MONOVISC

Acid, Hyaluronic, Intraarticular

FDA Premarket Approval P090031

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the monovisc injectable intra-articular device. This device is indicated for the treatment of pain in osteoarthritis (oa) of the knee in patients who have failed to respond adequately toconservative non-pharmacologic therapy and to simple analgesics (e. G. , acetaminophen).

DeviceMONOVISC
Classification NameAcid, Hyaluronic, Intraarticular
Generic NameAcid, Hyaluronic, Intraarticular
ApplicantAnika Therapeutics, Inc.
Date Received2009-12-29
Decision Date2014-02-25
Notice Date2014-03-05
PMAP090031
SupplementS
Product CodeMOZ
Docket Number14M-0254
Advisory CommitteeOrthopedic
Expedited ReviewNo
Combination Product No
Applicant Address Anika Therapeutics, Inc. 32 Wiggins Avenue bedford, MA 01730
Summary:Summary of Safety and Effectiveness
Labeling: Labeling Labeling Part 2
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P090031Original Filing
S015 2022-10-12 30-day Notice
S014 2022-10-03 30-day Notice
S013 2022-06-17 30-day Notice
S012 2021-09-15 30-day Notice
S011 2021-09-15 30-day Notice
S010 2021-08-11 30-day Notice
S009 2019-07-19 Normal 180 Day Track
S008 2017-05-23 Real-time Process
S007 2016-08-24 30-day Notice
S006 2016-02-10 Special (immediate Track)
S005
S004 2014-12-24 135 Review Track For 30-day Notice
S003 2014-11-07 Real-time Process
S002 2014-06-10 30-day Notice
S001 2014-05-08 30-day Notice

NIH GUDID Devices

Device IDPMASupp
05060548950033 P090031 000
05060459970090 P090031 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.